Paper10071301
Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
Dumontet C and 1 other. J Clin Oncol, 1999. Cited by 478 papers, by iCite.
Cite this record
ConductScience Library. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Papers, record 10071301. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10071301
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Apoptosis | Major topic |
| Microtubules | Major topic |
| Tubulin Modulators | Major topic |
| Amino Acid Sequence | |
| Animals | |
| Binding Sites | |
| Drug Resistance | |
| Humans | |
| Molecular Sequence Data | |
| Paclitaxel | |
| Tubulin | |
| Vinca Alkaloids |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA 52168 | NCI NIH HHS | United States | R01CA052168 | PubMed and NIH | NIH RePORTER |
| R01 CA 68217 | NCI NIH HHS | United States | R01CA068217 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00222404 | Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma" | Background |
Source ClinicalTrials.gov
Cited by168
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 478 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39941535 | The Use of Nerve Conduction Study to Evaluate the Effects of Frozen Sock Treatment on Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Prospective Clinical Trial. | J Clin Med | 2025 | https://conductscience.org/library/papers/39941535 | PubMed |
| 39525629 | Dopamine internalization via Uptake2 and stimulation of intracellular D5-receptor-dependent calcium mobilization and CDP-diacylglycerol signaling. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39525629 | PubMed |
| 39215442 | The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance. | Cancer Control | 2024 | https://conductscience.org/library/papers/39215442 | PubMed |
| 39174604 | Incidence and prognosis of taxane-induced macular edema: a retrospective study from the Japan Clinical REtina Study Group (J-CREST). | Sci Rep | 2024 | https://conductscience.org/library/papers/39174604 | PubMed |
| 38934894 | Cabazitaxel-Loaded Thermosensitive Hydrogel System for Suppressed Orthotopic Colorectal Cancer and Liver Metastasis. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38934894 | PubMed |
| 38560520 | Kinesin-7 CENP-E in tumorigenesis: Chromosome instability, spindle assembly checkpoint, and applications. | Front Mol Biosci | 2024 | https://conductscience.org/library/papers/38560520 | PubMed |
| 37930483 | Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview. | Biometals | 2024 | https://conductscience.org/library/papers/37930483 | PubMed |
| 37522022 | Meibomian gland changes in breast cancer patients treated with docetaxel-partial results. | Rom J Ophthalmol | 2023 | https://conductscience.org/library/papers/37522022 | PubMed |
| 37251731 | Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. | 3 Biotech | 2023 | https://conductscience.org/library/papers/37251731 | PubMed |
| 37047597 | Investigation of the Antineoplastic Effects of 2-(4-Chlorophenyl)-13α-Estrone Sulfamate against the HPV16-Positive Human Invasive Cervical Carcinoma Cell Line SiHa. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047597 | PubMed |
| 37047342 | Involvement of Bcl-2 Family Proteins in Tetraploidization-Related Senescence. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047342 | PubMed |
| 35897820 | Curcumin Induces Apoptosis of Chemoresistant Lung Cancer Cells via ROS-Regulated p38 MAPK Phosphorylation. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35897820 | PubMed |
| 35660840 | Cytotoxicity of phenylpironetin analogs and the metabolic fate of pironetin and phenylpironetin. | Bioorg Chem | 2022 | https://conductscience.org/library/papers/35660840 | PubMed |
| 35141015 | 5-arylalkynyl-2-benzoyl thiophene: a novel microtubule inhibitor exhibits antitumor activity without neurological toxicity. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/35141015 | PubMed |
| 35031699 | Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. | Acta Pharmacol Sin | 2022 | https://conductscience.org/library/papers/35031699 | PubMed |
| 34995063 | Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes. | Inorg Chem | 2022 | https://conductscience.org/library/papers/34995063 | PubMed |
| 34626303 | Development of a proteochemometric-based support vector machine model for predicting bioactive molecules of tubulin receptors. | Mol Divers | 2022 | https://conductscience.org/library/papers/34626303 | PubMed |
| 34541464 | Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells. | Cancer Drug Resist | 2020 | https://conductscience.org/library/papers/34541464 | PubMed |
| 34485522 | 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Tubulin Inhibitors with Potential Anticancer Activity. | Biomed Res Int | 2021 | https://conductscience.org/library/papers/34485522 | PubMed |
| 34423112 | Thiophene derivative-loaded nanoparticles mediate anticancer activity through the inhibition of kinases and microtubule assembly. | Adv Ther (Weinh) | 2021 | https://conductscience.org/library/papers/34423112 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PGP | 283871 | PubTator's text mining | https://conductscience.org/library/genes/283871 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10071301
GET https://conductscience.org/api/papers/v1/10071301/cited_by?page=2